Abstract: The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response.
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
October 5, 2010
Assignee:
Leiden University Medical Center
Inventors:
Sjoerd Hendricus van der Burg, Rienk Offringa, Cornelis Johannes Maria Melief, Theodorus Jozef Maria Helmerhorst
Abstract: Analogs or derivatives of nitrobenzylthioinosine corresponding to formula I: in which R represents an unsubstituted or mono- or polysubstituted phenyl, benzyl or heteroaryl group or a phenyl group condensed with heteroaryl, and R? represents an unsubstituted or mono- or polysubstituted NH—C1-6-alkyl, NH-aryl, NH-heteroaryl, NH—C3-8-cycloalkyl, NH—C1-3-alkyl-aryl, NH—C1-3-alkyl-heteroaryl, N(C1-6-alkyl)2, N(C1-3-alkyl-aryl)2, N(C1-3-alkyl-heteroaryl)2, piperidine, piperazine, morpholine or pyrrolidine group; pharmaceutical compositions comprising such analogs or derivatives, and the use of such analogs or derivatives for treating pain and/or various other diseases.
Abstract: The invention relates to the field of stem cell transplantations, immunotherapy and prophylaxis of neoplastic disease. Provided are peptides comprising an amino acid sequence encoded by an open reading frame as present in the nucleotide sequence of a transcript of a naturally occurring hADIR allele, wherein the amino acid sequence comprises a polymorphic MHC class I or II minor histocompatibility binding peptide.
Type:
Application
Filed:
February 22, 2007
Publication date:
September 3, 2009
Applicant:
Leiden University Medical Center
Inventors:
Cornelis Adreanus Maria Van Bergen, Michel George Dideric Kester, Petrus Antonius Van Veelen, Johan Herman Frederik Falkenburg
Abstract: The invention relates to the production of new Plasmodium mutants which are defective in the expression of the protein P36p. These mutants are unable to cause malaria, yet they can be used as vaccine, giving long lasting protection against infections with wild-type Plasmodium.
Type:
Grant
Filed:
August 14, 2007
Date of Patent:
June 23, 2009
Assignees:
Leiden University Medical Center, Stichting Katholieke Universiteit Nijmegen
Inventors:
Andrew Paul Waters, Christofel Jan Janse, Melissa Ruth van Dijk, Robert W. Sauerwein
Abstract: Analogs or derivatives of nitrobenzylthioinosine compounds. The use of these new analogs of nitrobenzylthioinosine and methods for the treatment of pain and various other indications using these analogs of nitrobenzylthioinosine as well as pharmaceutical compositions including analogs of nitrobenzylthioinosine.
Abstract: Analogs or derivatives of nitrobenzylthioinosine, pharmaceutical compositions comprising such analogs or derivatives, and the use of such analogs or derivatives of nitrobenzylthioinosine for the treatment of pain and various other diseases.
Abstract: For the early detection of blindness-causing diabetic retinopathy, an apparatus for measuring the autofluorescence of the cornea of an eye, comprising means for tangentially illuminating the cornea, means for receiving the autofluorescent radiation generated in the cornea by this illumination, and means for processing the measured autofluorescent radiation, wherein the means for tangentially illuminating the cornea comprises at least one light source which radiates blue light and at least one filter which transmits at least a part of the blue light in a light path to the cornea, and the means for receiving the autofluorescent radiation generated in the cornea comprises at least one filter which transmits green light.
Abstract: New peptides derived from the MAGE-2 molecule and which bind to HLA-A*0201 molecules are disclosed. Some of these are especially useful because, when complexed to their HLA-A*0201 partner molecules, they induce CTL proliferation.
Type:
Grant
Filed:
July 25, 1996
Date of Patent:
November 11, 1997
Assignees:
Ludwig Institute for Cancer Research, Leiden University
Inventors:
Cornelius J. M. Melief, M. W. Visseren, Sjoerd van der Burg, Pierre van der Bruggen, Thierry Boon-Falleur